Loading...

Intellia Therapeutics

DB:38I
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
38I
DB
$739M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The last earnings update was 55 days ago. More info.


Add to Portfolio Compare Print
38I Share Price and Events
7 Day Returns
-3.3%
DB:38I
-2.7%
DE Biotechs
1.5%
DE Market
1 Year Returns
-10.9%
DB:38I
-10.6%
DE Biotechs
-6.2%
DE Market
38I Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Intellia Therapeutics (38I) -3.3% -5.6% 15.7% -10.9% - -
DE Biotechs -2.7% 3.8% -8.5% -10.6% 47.4% 10.3%
DE Market 1.5% 6% 8.5% -6.2% 10.7% 15.3%
1 Year Return vs Industry and Market
  • 38I underperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
38I
Industry
5yr Volatility vs Market
Related Companies

38I Value

 Is Intellia Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Intellia Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €14.645.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Intellia Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Intellia Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:38I PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.98
NasdaqGM:NTLA Share Price ** NasdaqGM (2019-04-23) in USD $16.96
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.6x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Intellia Therapeutics.

DB:38I PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:NTLA Share Price ÷ EPS (both in USD)

= 16.96 ÷ -1.98

-8.56x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Intellia Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Intellia Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Intellia Therapeutics's expected growth come at a high price?
Raw Data
DB:38I PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -8.56x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
-16.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Intellia Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Intellia Therapeutics's assets?
Raw Data
DB:38I PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $6.15
NasdaqGM:NTLA Share Price * NasdaqGM (2019-04-23) in USD $16.96
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:38I PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:NTLA Share Price ÷ Book Value per Share (both in USD)

= 16.96 ÷ 6.15

2.76x

* Primary Listing of Intellia Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Intellia Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Intellia Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Intellia Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

38I Future Performance

 How is Intellia Therapeutics expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-16.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Intellia Therapeutics expected to grow at an attractive rate?
  • Unable to compare Intellia Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Intellia Therapeutics's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Intellia Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:38I Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:38I Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts -16.7%
DB:38I Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 18.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:38I Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:38I Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 32 -134 -225 3
2022-12-31 102 -101 -167 5
2021-12-31 78 -138 -164 4
2020-12-31 46 -88 -133 7
2019-12-31 35 -71 -113 7
DB:38I Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 30 -61 -85
2018-09-30 29 -74 -90
2018-06-30 29 -78 -83
2018-03-31 27 -72 -76
2017-12-31 26 -65 -68
2017-09-30 25 -58 -54
2017-06-30 23 -49 -46
2017-03-31 21 34 -38
2016-12-31 16 36 -32
2016-09-30 13 45 -26
2016-06-30 9 49 -22
2016-03-31 7 -16 -18

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Intellia Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Intellia Therapeutics's revenue is expected to grow by 18.4% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:38I Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from Intellia Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:38I Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -2.91 -2.65 -3.16 2.00
2022-12-31 -2.62 -1.90 -3.35 3.00
2021-12-31 -2.79 -2.00 -3.53 4.00
2020-12-31 -2.79 -1.68 -3.81 6.00
2019-12-31 -2.25 -1.30 -2.78 5.00
DB:38I Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.98
2018-09-30 -2.16
2018-06-30 -2.08
2018-03-31 -2.02
2017-12-31 -1.88
2017-09-30 -1.55
2017-06-30 -1.33
2017-03-31 -1.22
2016-12-31 -1.42
2016-09-30 -1.92
2016-06-30 -4.54
2016-03-31 -80.62

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Intellia Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Intellia Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Intellia Therapeutics has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

38I Past Performance

  How has Intellia Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Intellia Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Intellia Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Intellia Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Intellia Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Intellia Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Intellia Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:38I Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 30.43 -85.34 32.19
2018-09-30 29.22 -90.24 33.69
2018-06-30 29.13 -82.89 31.14
2018-03-31 27.37 -76.27 29.70
2017-12-31 26.12 -67.54 28.03
2017-09-30 25.08 -54.14 22.93
2017-06-30 22.63 -46.27 21.92
2017-03-31 20.92 -37.58 19.28
2016-12-31 16.48 -31.63 16.80
2016-09-30 12.55 -26.32 14.49
2016-06-30 9.36 -21.85 11.32
2016-03-31 6.54 -17.99 10.42
2015-12-31 6.04 -12.40 8.28
2015-09-30 4.35 -14.37 8.19
2014-12-31 -14.31 3.57

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Intellia Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Intellia Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Intellia Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Intellia Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Intellia Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

38I Health

 How is Intellia Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Intellia Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Intellia Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Intellia Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Intellia Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Intellia Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Intellia Therapeutics Company Filings, last reported 3 months ago.

DB:38I Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 277.92 0.00 314.06
2018-09-30 263.27 0.00 293.25
2018-06-30 279.34 0.00 305.54
2018-03-31 295.50 0.00 327.78
2017-12-31 300.60 0.00 340.68
2017-09-30 175.85 0.00 222.26
2017-06-30 187.59 0.00 241.05
2017-03-31 199.88 0.00 257.55
2016-12-31 209.84 0.00 273.06
2016-09-30 218.12 0.00 290.62
2016-06-30 223.60 0.00 300.69
2016-03-31 61.48 0.00 64.19
2015-12-31 67.36 0.00 75.82
2015-09-30 72.26 0.00 82.61
2014-12-31 7.57 0.00 9.85
  • Intellia Therapeutics has no debt.
  • Intellia Therapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Intellia Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
  • Intellia Therapeutics has sufficient cash runway for 2.6 years if free cash flow continues to grow at historical rates of 78.8% each year.
X
Financial health checks
We assess Intellia Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Intellia Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

38I Dividends

 What is Intellia Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Intellia Therapeutics dividends. Estimated to be 0% next year.
If you bought €2,000 of Intellia Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Intellia Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Intellia Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:38I Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:38I Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Intellia Therapeutics has not reported any payouts.
  • Unable to verify if Intellia Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Intellia Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Intellia Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Intellia Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Intellia Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Intellia Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Intellia Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

38I Management

 What is the CEO of Intellia Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
John Leonard
COMPENSATION $2,592,874
AGE 61
TENURE AS CEO 1.3 years
CEO Bio

Dr. John M. Leonard, M.D., has been a Director at IQVIA Holdings Inc. since February 2015 and has been its Lead Director since July 25, 2018. Dr. Leonard has been the President and Chief Executive Officer of Intellia Therapeutics Inc. since January 1, 2018. He served as Executive Vice President of Research & Development at Intellia since January 13, 2017 and served as its Chief Medical Officer since joining in July 2014 until January 13, 2017. Dr. Leonard is an Executive Partner at Tyree & D'Angelo Partners. He spent over 22 years at AbbVie and Abbott Laboratories from 1992, until his retirement from AbbVie in 2013. Dr. Leonard served as the Chief Scientific Officer and Senior Vice President at AbbVie Inc. Dr. Leonard served as a Senior Vice President of Pharmaceuticals, Research and Development at AbbVie Inc. He served as Senior Vice President of Pharmaceuticals, Research and Development at Abbott Diabetes Care, Inc. from February 2008 to 2012. Dr. Leonard served as Senior Vice President of Pharmaceuticals, Research and Development at Abbott Laboratories since February 2008. While serving as the Global Head of Pharmaceutical R&D at Abbott Laboratories, he oversaw the development of numerous novel therapeutics. His ground-breaking work with HIV protease inhibitors Norvir and Kaletra led to new treatment paradigms for AIDS, while his years of work with Humira made it the all-time top-selling drug worldwide. Dr. Leonard served as Vice President of Global Medical & Scientific Affairs at Abbott Laboratories. He served as Vice President of Global Pharmaceutical Drug Development at Abbott Laboratories since 2001 and also Vice President of Pharmaceutical Development from 1999 to 2001, Divisional Vice President, Pharmaceutical Development, Pharmaceutical Products Research and Development from 1998 to 1999 and served as its Corporate Officer since 1999. Since joining Abbott in 1992 as Head of the Antiviral Venture in the Pharmaceutical Products Division, Dr. Leonard has held several positions in the same division. Prior to joining Abbott, he served as Senior Director for Clinical Research at G.H. Besselaar Associates. He served as Chairman of the Supervisory Board of Abbott Germany. Dr. Leonard serves as Director of Quintiles Transnational, Inc. He has been a Director of Quintiles Transnational Holdings Inc. since February 5, 2015. He served as a Director of Intellia Therapeutics Inc. Dr. Leonard was a Director of Chimerix Inc. until June 20, 2018. He has been a Director of Quintiles Transnational Holdings Inc. since February 5, 2015. Dr. Leonard serves as a Director of Biotechnology Innovation Organization. He is a Director of the National Association for Biomedical Research (NABR). Dr. Leonard served as Member of Scientific Advisory Board at Verseon Corporation until 2019. He served as a Director of Vitae Pharmaceuticals, Inc. from July 29, 2015 to October 25, 2016. Dr. Leonard served as a Board Member of a number of organizations including Reata Pharmaceutical. He served as a Director of Arisaph Pharmaceuticals, Inc., since 2007. Dr. Leonard has a 30-year career in pharmaceutical R&D, healthcare management, research and development and medicine. He is among the leading R&D executives who have not only introduced breakthrough medicines, but also guided their development into mega-blockbuster drugs. Dr. Leonard is board certified in Internal Medicine and is licensed to practice in Illinois and Maryland. He completed an Internship and Residency in Internal Medicine at Stanford University Hospital followed by a Postdoctoral Fellowship in Molecular Virology at the National Institute of Allergy and Infectious Diseases at the National Institutes of Health. Dr. Leonard earned an MD from Johns Hopkins University in Baltimore, MD. and BA degree in biochemistry from the University of Wisconsin at Madison.

CEO Compensation
  • John's compensation has increased whilst company is loss making.
  • John's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Intellia Therapeutics management team in years:

4.8
Average Tenure
52
Average Age
  • The tenure for the Intellia Therapeutics management team is about average.
Management Team

John Leonard

TITLE
President
COMPENSATION
$3M
AGE
61
TENURE
1.3 yrs

Nessan Bermingham

TITLE
Founder & Member of Scientific Advisor Board
COMPENSATION
$11M
AGE
45
TENURE
4.9 yrs

José Rivera

TITLE
Executive VP & General Counsel
COMPENSATION
$3M
AGE
52
TENURE
4.8 yrs

Rachel Haurwitz

TITLE
Co-Founder
COMPENSATION
$312K
AGE
32
TENURE
4.9 yrs

Andy May

TITLE
Founder and Member of Scientific Advisor Board

Jennifer Doudna

TITLE
Founder & Member of Scientific Advisor Board
AGE
54

Derrick Rossi

TITLE
Founder & Member of Scientific Advisor Board

Rodolphe Barrangou

TITLE
Founder & Member of Scientific Advisor Board

Luciano Marraffini

TITLE
Founder & Member of Scientific Advisor Board

Erik Sontheimer

TITLE
Founder & Member of Scientific Advisor Board
Board of Directors Tenure

Average tenure and age of the Intellia Therapeutics board of directors in years:

4
Average Tenure
61
Average Age
  • The tenure for the Intellia Therapeutics board of directors is about average.
Board of Directors

Perry Karsen

TITLE
Chairman
COMPENSATION
$274K
AGE
63
TENURE
3 yrs

John Leonard

TITLE
President
COMPENSATION
$3M
AGE
61
TENURE
4.8 yrs

Nessan Bermingham

TITLE
Founder & Member of Scientific Advisor Board
COMPENSATION
$11M
AGE
45

Andy May

TITLE
Founder and Member of Scientific Advisor Board

Jennifer Doudna

TITLE
Founder & Member of Scientific Advisor Board
AGE
54
TENURE
4 yrs

Derrick Rossi

TITLE
Founder & Member of Scientific Advisor Board
TENURE
4 yrs

Rodolphe Barrangou

TITLE
Founder & Member of Scientific Advisor Board

Luciano Marraffini

TITLE
Founder & Member of Scientific Advisor Board

Erik Sontheimer

TITLE
Founder & Member of Scientific Advisor Board

Jean-François Formela

TITLE
Director
COMPENSATION
$202K
AGE
61
TENURE
4.9 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Intellia Therapeutics insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
12. Mar 19 Buy Andrew Schiermeier Individual 06. Mar 19 06. Mar 19 7,500 €14.14 €104,154
17. May 18 Sell Atlas Venture L.P. Company 16. May 18 16. May 18 -6,686 €21.24 €-142,030
X
Management checks
We assess Intellia Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Intellia Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

38I News

Simply Wall St News

38I Company Info

Description

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells; and acute myeloid leukemia. Intellia Therapeutics, Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Ospedale San Raffaele; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Details
Name: Intellia Therapeutics, Inc.
38I
Exchange: DB
Founded: 2014
$659,109,284
45,479,098
Website: http://www.intelliatx.com
Address: Intellia Therapeutics, Inc.
40 Erie Street,
Suite 130,
Cambridge,
Massachusetts, 02139,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM NTLA Common Stock Nasdaq Global Market US USD 06. May 2016
DB 38I Common Stock Deutsche Boerse AG DE EUR 06. May 2016
LSE 0JBU Common Stock London Stock Exchange GB USD 06. May 2016
Number of employees
Current staff
Staff numbers
211
Intellia Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/23 22:15
End of day share price update: 2019/04/23 00:00
Last estimates confirmation: 2019/04/22
Last earnings filing: 2019/02/27
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.